Business Wire

OH-GE-AEROSPACE

19.6.2024 08:01:30 CEST | Business Wire | Press release

Share
GE Aerospace Announces Voluntary Delisting of GE Common Stock from Euronext Paris, the London Stock Exchange and the SIX Swiss Exchange

GE AEROSPACE (GENERAL ELECTRIC COMPANY; NYSE: GE) announced today that, as part of a simplification project following the launch of GE Aerospace as an independent public company, it has submitted applications for the delisting of GE common stock (ISIN Code US3696043013) from Euronext Paris, the London Stock Exchange and the SIX Swiss Exchange (the “Delisting”). This action follows a comprehensive review of the trading volume, cost and administrative requirements related to these listings. Following the Delisting, GE Aerospace shares will continue to be traded on the New York Stock Exchange (“NYSE”), GE Aerospace’s primary listing exchange.

The following required information is provided in connection with the Delisting from Euronext Paris. The Delisting has been approved by the Listing Board of Euronext Paris S.A.

Information Regarding Delisting Procedure for Euronext Paris

A sales facility procedure (the “Sales Facility”) will be put in place from 21 June 2024 to 19 July 2024 (the “Sales Facility Period”) to allow shareholders to sell on the NYSE their GE Aerospace shares which are listed on Euronext Paris and held in the Euroclear France clearing system (the “GE Aerospace Euronext Shares”). GE Aerospace has appointed Uptevia to act as centralizing agent under the Sales Facility (the “Centralizing Agent”).

During the Sales Facility Period, shareholders with GE Aerospace Euronext Shares will have the following options:

  • sell on a voluntary basis all or part of their GE Aerospace Euronext Shares on the NYSE by participating in the Sales Facility (described in more detail below); or
  • retain all or part of their GE Aerospace Euronext Shares, which will continue to be traded on Euronext Paris during the entire Sales Facility Period until and including the trading day prior to the date of the Delisting.

The GE Aerospace Euronext Shares will be delisted from Euronext Paris on 25 July 2024 (the “Delisting Date”).

Shareholders not participating

Shareholders who do not wish to sell their GE Aerospace Euronext Shares under the Sales Facility or directly on Euronext Paris, or have otherwise taken no action by the Delisting Date, will be able to trade their GE Aerospace Euronext Shares on the NYSE, subject to the terms and conditions applied by their financial intermediaries.

Participating shareholders

Shareholders who wish to sell their GE Aerospace Euronext Shares on the NYSE under the Sales Facility should request their financial intermediaries to deliver their GE Aerospace Euronext Shares during the Sales Facility Period to the Centralizing Agent, pursuant to the procedure described below.

The GE Aerospace Euronext Shares delivered to the Centralizing Agent during the Sales Facility Period will be sold on the NYSE as from 26 July 2024 by a broker, at market prices prevailing at the time of the sale. The Centralizing Agent will calculate the average sale price of the GE Aerospace Euronext Shares and will be in charge of transferring the sale proceeds (which will be converted into euros from U.S. dollars by Uptevia) to the GE Aerospace shareholders participating in the Sales Facility once it has received the funds for the sale of all of the GE Aerospace Euronext Shares tendered under the Sales Facility.

GE Aerospace will pay the brokerage commissions on the NYSE for the sale of GE Aerospace Euronext Shares tendered pursuant to the Sales Facility, the fee of the Centralizing Agent and any applicable foreign exchange commission that would be incurred in connection with the Sales Facility.

The Sales Facility procedure is also described in a Euronext notice to be published on 19 June 2024.

No guarantee can be given by GE Aerospace or by the Centralizing Agent as to the price at which the GE Aerospace Euronext Shares tendered pursuant to the Sales Facility will be sold. The Sales Facility is being provided solely as an accommodation to holders of GE Aerospace Euronext Shares. Holders (and in particular individual investors) of GE Aerospace Euronext Shares may decide not to participate in the Sales Facility or may decide not to take any action, in which case no guarantee can be given on the terms, including costs, that would be applied by their financial intermediary after the Delisting. Individual investors are urged to consult their own investment advisors before deciding to participate or not in this process.

The contemplated timetable of the Sales Facility and the Delisting can be summarized as follows (it being specified that GE Aerospace reserves the right to amend this calendar):

Event

Date

Sales Facility

Beginning of the Sales Facility

21 June 2024

End of the Sales Facility

19 July 2024

End of the centralization by Uptevia

23 July 2024

Sale on the NYSE of the GE Aerospace Euronext Shares tendered in the Sales Facility

As from 26 July 2024

Settlement of the proceeds of the Sales Facility to the relevant financial intermediary

As soon as possible after receipt of the proceeds of the Sales Facility

Delisting

Last day of trading of GE Aerospace Euronext Shares on Euronext Paris

24 July 2024

Delisting of GE Aerospace Euronext Shares on Euronext Paris

25 July 2024

GE Aerospace shareholders participating in the Sales Facility are reminded that they acknowledge and accept (i) the risk implied from the change in the share market price and/or applicable exchange rates between the date on which their shares are delivered to Uptevia for participation in the Sales Facility and the receipt of the applicable average sale proceeds, and (ii) that from the time the GE Aerospace Euronext Shares are delivered to Uptevia, they will not be entitled to any subsequent dividend declared by GE Aerospace. They are also reminded that any orders to tender GE Aerospace Euronext Shares to the Sales Facility are irrevocable, as is the subsequent sale of such GE Aerospace Euronext Shares tendered on the NYSE.

Shareholders may request any additional information from their custodian and usual financial intermediary, who has received the details of the Delisting.

About GE AEROSPACE

GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 44,000 commercial and 26,000 military aircraft engines. With a global team of 52,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow and the future at www.geaerospace.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618573691/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release

Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer

TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the

Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse

Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste

Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye